Literature DB >> 14744930

PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.

Michael J Ryan1, Sean P Didion, Satya Mathur, Frank M Faraci, Curt D Sigmund.   

Abstract

The peroxisome proliferator activated receptor (PPARgamma) agonist rosiglitazone has been reported to yield cardiovascular benefits in patients by a mechanism that is not completely understood. We tested whether oral rosiglitazone (25 mg/kg per day, 21 days) treatment improves blood pressure and vascular function in a transgenic mouse expressing both human renin and human angiotensinogen transgenes (R(+)A(+)). Rosiglitazone decreased systolic (138+/-5 versus 128+/-5 mm Hg) and mean blood pressure (145+/-5 versus 126+/-7 mm Hg) of R(+)A(+) mice as measured by tail-cuff and indwelling carotid catheters, respectively. Relaxation of carotid arteries to acetylcholine and authentic nitric oxide, but not papaverine, was impaired in R(+)A(+) mice when compared with littermate controls (RA(-)). There were no effects of rosiglitazone on RA(-) mice; however, relaxation to acetylcholine (49+/-10 versus 82+/-9% at 100 micromol/L) and nitric oxide (51+/-11 versus 72+/-6% at 10 micromol/L) was significantly improved in treated R(+)A(+) mice. Rosiglitazone treatment of R(+)A(+) mice did not alter the expression of genes, including endothelial nitric oxide synthase (eNOS), angiotensin 1 receptors, and preproendothelin-1, nor did it alter the levels of eNOS or soluble guanylyl cyclase protein. In separate studies, carotid arteries from R(+)A(+) and RA(-) mice relaxed in a concentration-dependent manner to rosiglitazone, suggesting possible PPARgamma-independent effects in the vasculature. This response was not inhibited with the nitric oxide synthase inhibitor N(omega)-nitro-l-arginine methyl ester (200 micromol/L) or the PPARgamma antagonist bisphenol A diglycidyl ether; 4,4'-isopropylidenediphenol diglycidyl ether (100 micromol/L). These data suggest that in addition to potential genomic regulation caused by PPARgamma activation, the direct effect of rosiglitazone in blood vessels may contribute to the improved blood pressure and vessel function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744930     DOI: 10.1161/01.HYP.0000116303.71408.c2

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  64 in total

Review 1.  Role of renal proximal tubule transport in thiazolidinedione-induced volume expansion.

Authors:  George Seki; Yoko Endo; Masashi Suzuki; Hideomi Yamada; Shoko Horita; Toshiro Fujita
Journal:  World J Nephrol       Date:  2012-10-06

Review 2.  Protecting against vascular disease in brain.

Authors:  Frank M Faraci
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-18       Impact factor: 4.733

3.  Context-dependent effects of SOCS3 in angiotensin II-induced vascular dysfunction and hypertension in mice: mechanisms and role of bone marrow-derived cells.

Authors:  Ying Li; Dale A Kinzenbaw; Mary L Modrick; Lecia L Pewe; Frank M Faraci
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-04-22       Impact factor: 4.733

Review 4.  Impact of thiazolidinedione therapy on atherogenesis.

Authors:  Jeroen P H van Wijk; Ton J Rabelink
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 5.  PPARgamma in human and mouse physiology.

Authors:  Sami Heikkinen; Johan Auwerx; Carmen A Argmann
Journal:  Biochim Biophys Acta       Date:  2007-03-27

6.  Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.

Authors:  Hongyu Zhang; Jharna Saha; Jaeman Byun; MaryLee Schin; Matthew Lorenz; Robert T Kennedy; Matthias Kretzler; Eva L Feldman; Subramaniam Pennathur; Frank C Brosius
Journal:  Am J Physiol Renal Physiol       Date:  2008-07-30

Review 7.  Electrophilic nitro-fatty acids: anti-inflammatory mediators in the vascular compartment.

Authors:  Nicholas K H Khoo; Bruce A Freeman
Journal:  Curr Opin Pharmacol       Date:  2010-01-14       Impact factor: 5.547

8.  Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.

Authors:  Andreas M Beyer; Gary L Baumbach; Carmen M Halabi; Mary L Modrick; Cynthia M Lynch; Thomas D Gerhold; Shams M Ghoneim; Willem J de Lange; Henry L Keen; Yau-Sheng Tsai; Nobuyo Maeda; Curt D Sigmund; Frank M Faraci
Journal:  Hypertension       Date:  2008-02-19       Impact factor: 10.190

9.  Role of sex steroids in modulating tumor necrosis factor alpha-induced changes in vascular function and blood pressure.

Authors:  Babbette D LaMarca; Derrick L Chandler; Lee Grubbs; Jennifer Bain; Gerald R McLemore; Joey P Granger; Michael J Ryan
Journal:  Am J Hypertens       Date:  2007-11       Impact factor: 2.689

10.  Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet.

Authors:  Andreas M Beyer; Willem J de Lange; Carmen M Halabi; Mary L Modrick; Henry L Keen; Frank M Faraci; Curt D Sigmund
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.